Compare State Street SPDR S&P Biotech ETF (XBI) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs 22nd Century Group Inc — how do they compare? State Street SPDR S&P Biotech ETF trades at $154.5, while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). Which is the better fit depends on your goals.
| XBI | XXII | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $164.28 | $1.07K |
52-Week Low | $85.16 | $3.90 |
Market Cap | — | $1.49M |
Enterprise Value | — | -$6.74M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
